Ian Smith

Ian Frederick Smith is Chief Executive Officer & Director at Stoke Therapeutics, Inc. starting 2025.
Holds the position of Executive Chairman at Solid Biosciences, Inc. since 2022.
Chairman at iVexSol, Inc. and Rivus Pharmaceuticals, Inc. since 2023.
Director at Vertex Pharmaceuticals (Canada), Inc. and Vertex Pharmaceuticals (U.K.) Ltd. since 2011.
Independent Director at Foghorn Therapeutics, Inc. since 2021.
Director at Alkeus Pharmaceuticals, Inc. since 2022 and Areteia Therapeutics, Inc. starting 2025.
Independent Director at Odyssey Therapeutics, Inc. starting 2024.
Member of The Institute of Chartered Accountants in England & Wales, The American Institute of Certified Public Accountants, and The Financial Executives Institute.
Senior Advisor at Bain Capital Life Sciences LP.
Former Executive Chairman at ViaCyte, Inc. from 2020 to 2022.
Director at EPIX Pharmaceuticals, Inc. Former Director at Tolerx, Inc. from 2004 to 2011.
Independent Director at Acorda Therapeutics, Inc. from 2011 to 2019.
Director at Predix Pharmaceuticals, Inc. from 2005 to 2006.
Independent Director at Infinity Pharmaceuticals, Inc. from 2011 to 2019.
Director at Vertex Pharmaceuticals (Europe) Ltd. from 2011 to 2019.
Independent Director at IVERIC bio, Inc. from 2016 to 2017.
Co-Managing Director at Vertex Pharmaceuticals (Germany) GmbH.
Director at AavantiBio, Inc. Partner-Life Science & Technology Practice Group at Ernst & Young LLP from 1999 to 2001.
EVP, Chief Operating & Financial Officer at Vertex Pharmaceuticals, Inc. from 2018 to 2019.
Completed undergraduate degree at Manchester Metropolitan University.